This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2029 Remove Disease Remove Regulations Remove Therapies
article thumbnail

Diabetic eye disease: The urgent need for early, non-invasive treatments

Drug Discovery World

MAY 15, 2024

Dr Catherine Beech , CEO at Exonate and Dr Pete Adamson , CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Specific numerical values (steps) denote the severity of NPDR, with 47-53 describing the moderately severe disease.

Disease 162
Disease Treatment Therapies Pharmaceuticals 162
article thumbnail

The politics of health: How 2024 elections will impact life sciences

Drug Discovery World

JULY 26, 2024

This, coupled with looming patent expirations, the impact of new drug pricing regulations, and tighter universal regulation of medical devices presents a complex environment for both large and small life science companies. With an anticipated annual growth rate of 7.61%, they are predicted to reach US$12.57bn by 2029.

Science 130
Science Government Biosimilars Marketing 130
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 42,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024